Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins, Lancet, vol.366, pp.1267-1278, 2005. ,
Primary Prevention of Cardiovascular Mortality and Events With Statin Treatments, Journal of the American College of Cardiology, vol.52, issue.22, pp.1769-1781, 2008. ,
DOI : 10.1016/j.jacc.2008.08.039
Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis, Lancet, vol.371, pp.117-125, 2008. ,
The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: An updated meta-analysis, Clinical Therapeutics, vol.31, issue.2, pp.236-244, 2009. ,
DOI : 10.1016/j.clinthera.2009.02.017
Meta-Analysis of Cardiovascular Outcomes Trials Comparing Intensive Versus Moderate Statin Therapy, Journal of the American College of Cardiology, vol.48, issue.3, pp.438-445, 2006. ,
DOI : 10.1016/j.jacc.2006.04.070
Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials, Heart, vol.93, issue.8, pp.914-921, 2007. ,
DOI : 10.1136/hrt.2006.112508
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study, The Lancet, vol.364, issue.9438, pp.937-952, 2004. ,
DOI : 10.1016/S0140-6736(04)17018-9
Abdominal Obesity and Dyslipidemia in the Metabolic Syndrome: Importance of Type 2 Diabetes and Familial Combined Hyperlipidemia in Coronary Artery Disease Risk, The Journal of Clinical Endocrinology & Metabolism, vol.89, issue.6, pp.2601-2607, 2004. ,
DOI : 10.1210/jc.2004-0432
Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both?, Cardiovascular Diabetology, vol.3, issue.1, p.10, 2004. ,
DOI : 10.1186/1475-2840-3-10
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines, Circulation, vol.110, issue.2, pp.227-239, 2004. ,
DOI : 10.1161/01.CIR.0000133317.49796.0E
AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update: Endorsed by the National Heart, Lung, and Blood Institute, Circulation, vol.113, issue.19, pp.2363-2372, 2006. ,
DOI : 10.1161/CIRCULATIONAHA.106.174516
Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A Scientific Statement From the American Heart Association and the American Diabetes Association, Circulation, vol.115, issue.1, pp.114-126, 2007. ,
DOI : 10.1161/CIRCULATIONAHA.106.179294
European guidelines on cardiovascular disease prevention in clinical practice: Executive summary, Atherosclerosis, vol.194, issue.1, pp.2375-2414, 2007. ,
DOI : 10.1016/j.atherosclerosis.2007.08.024
Fibrates and future PPAR?? agonists in the treatment of cardiovascular disease, Nature Clinical Practice Cardiovascular Medicine, vol.99, issue.9, pp.542-553, 2008. ,
DOI : 10.1038/ncpcardio1278
Pleiotropic Effects of Statins - Clinical Evidence, Current Pharmaceutical Design, vol.15, issue.5, pp.479-489, 2009. ,
DOI : 10.2174/138161209787315729
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein, New England Journal of Medicine, vol.359, issue.21, pp.2195-2207, 2008. ,
DOI : 10.1056/NEJMoa0807646
Fibrates and Microvascular Complications in Diabetes - Insight from the FIELD Study, Current Pharmaceutical Design, vol.15, issue.5, pp.537-552, 2009. ,
DOI : 10.2174/138161209787315701
Additive Beneficial Effects of Fenofibrate Combined With Atorvastatin in the Treatment of Combined Hyperlipidemia, Journal of the American College of Cardiology, vol.45, issue.10, pp.1649-1653, 2005. ,
DOI : 10.1016/j.jacc.2005.02.052
The Reduction of Inflammatory Biomarkers by Statin, Fibrate, and Combination Therapy Among Diabetic Patients With Mixed Dyslipidemia, Journal of the American College of Cardiology, vol.48, issue.2, pp.396-401, 2006. ,
DOI : 10.1016/j.jacc.2006.05.009
Baseline Low-Density Lipoprotein Cholesterol Is an Important Predictor of the Benefit of Intensive Lipid-Lowering Therapy, Journal of the American College of Cardiology, vol.52, issue.11, pp.914-920, 2008. ,
DOI : 10.1016/j.jacc.2008.05.046
Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): Comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes, American Heart Journal, vol.156, issue.5, pp.826-832, 2008. ,
DOI : 10.1016/j.ahj.2008.07.023
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial, The Lancet, vol.373, issue.9670, pp.1175-1182, 2009. ,
DOI : 10.1016/S0140-6736(09)60447-5
Influence of Low High-Density Lipoprotein Cholesterol and Elevated Triglyceride on Coronary Heart Disease Events and Response to Simvastatin Therapy in 4S, Circulation, vol.104, issue.25, pp.3046-3051, 2001. ,
DOI : 10.1161/hc5001.100624
The impact of residual CVD risk in the managed care setting, Am J Manag Care, vol.15, pp.74-80, 2009. ,
High density lipoprotein as a protective factor against coronary heart disease, The American Journal of Medicine, vol.62, issue.5, pp.707-714, 1977. ,
DOI : 10.1016/0002-9343(77)90874-9
HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events, New England Journal of Medicine, vol.357, issue.13, pp.1301-1310, 2007. ,
DOI : 10.1056/NEJMoa064278
Clinical Significance of High-Density Lipoprotein Cholesterol in Patients With Low Low-Density Lipoprotein Cholesterol, Journal of the American College of Cardiology, vol.51, issue.1, pp.49-55, 2008. ,
DOI : 10.1016/j.jacc.2007.07.086
Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis, JAMA, vol.297, issue.5, pp.499-508, 2007. ,
DOI : 10.1001/jama.297.5.499
Secondary Prevention With Bezafibrate Therapy for the Treatment of Dyslipidemia, Journal of the American College of Cardiology, vol.51, issue.4, pp.459-465, 2008. ,
DOI : 10.1016/j.jacc.2007.09.048
Long-term Benefit of High-Density Lipoprotein Cholesterol???Raising Therapy With Bezafibrate, Archives of Internal Medicine, vol.169, issue.5, pp.508-514, 2009. ,
DOI : 10.1001/archinternmed.2008.584
Fasting Compared With Nonfasting Triglycerides and Risk of Cardiovascular Events in Women, JAMA, vol.298, issue.3, pp.309-316, 2007. ,
DOI : 10.1001/jama.298.3.309
Triglycerides and Risk for Coronary Heart Disease, JAMA, vol.298, issue.3, pp.336-338, 2007. ,
DOI : 10.1001/jama.298.3.336
Triglycerides and the Risk of Coronary Heart Disease: 10 158 Incident Cases Among 262 525 Participants in 29 Western Prospective Studies, Circulation, vol.115, issue.4, pp.450-458, 2007. ,
DOI : 10.1161/CIRCULATIONAHA.106.637793
Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial, Journal of the American College of Cardiology, vol.51, issue.7, pp.724-730, 2008. ,
DOI : 10.1016/j.jacc.2007.10.038
Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, Diabetes Care, vol.32, issue.3, pp.493-498, 2009. ,
DOI : 10.2337/dc08-1543
Meta-Analysis of the Relationship Between Non???High-Density Lipoprotein Cholesterol Reduction and Coronary Heart Disease Risk, Journal of the American College of Cardiology, vol.53, issue.4, pp.316-322, 2009. ,
DOI : 10.1016/j.jacc.2008.10.024
Prognostic Utility of ApoB/AI, Total Cholesterol/HDL, Non-HDL Cholesterol, or hs-CRP as Predictors of Clinical Risk in Patients Receiving Statin Therapy After Acute Coronary Syndromes: Results From PROVE IT-TIMI 22, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.29, issue.3, pp.424-430, 2009. ,
DOI : 10.1161/ATVBAHA.108.181735
Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment, Circulation, vol.117, issue.23, pp.3002-3009, 2008. ,
DOI : 10.1161/CIRCULATIONAHA.107.713438
LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study???Implications for LDL management, Journal of Clinical Lipidology, vol.1, issue.6, pp.583-592, 2009. ,
DOI : 10.1016/j.jacl.2007.10.001
Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice, Journal of Clinical Lipidology, vol.2, issue.1, pp.36-42, 2008. ,
DOI : 10.1016/j.jacl.2007.12.006
Apolipoprotein B and Cardiovascular Disease Risk: Position Statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices, Clinical Chemistry, vol.55, issue.3, pp.407-419, 2009. ,
DOI : 10.1373/clinchem.2008.118356
Effects of Rosuvastatin and Atorvastatin on LDL and HDL Particle Concentrations in Patients With Metabolic Syndrome: A randomized, double-blind, controlled study, Diabetes Care, vol.32, issue.6, pp.1087-1091, 2009. ,
DOI : 10.2337/dc08-1681
Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia, American Heart Journal, vol.153, issue.2, pp.335-338, 2007. ,
DOI : 10.1016/j.ahj.2006.10.031
Treatment of hyperlipidaemia with fenofibrate and related fibrates, Expert Opinion on Investigational Drugs, vol.51, issue.10, pp.1599-1614, 2008. ,
DOI : 10.1016/j.jacl.2008.04.023
Fenofibrate Therapy Ameliorates Fasting and Postprandial Lipoproteinemia, Oxidative Stress, and the Inflammatory Response in Subjects With Hypertriglyceridemia and the Metabolic Syndrome, Diabetes Care, vol.30, issue.8, pp.1945-1951, 2007. ,
DOI : 10.2337/dc07-0015
Atorvastatin and Fenofibrate Have Comparable Effects on VLDL-Apolipoprotein C-III Kinetics in Men With the Metabolic Syndrome, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.28, issue.10 ,
DOI : 10.1161/ATVBAHA.108.170530
Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia, Metabolism, vol.57, issue.2, pp.246-254, 2008. ,
DOI : 10.1016/j.metabol.2007.09.008
Differential Regulation of Lipoprotein Kinetics by Atorvastatin and Fenofibrate in Subjects With the Metabolic Syndrome, Diabetes, vol.52, issue.3, pp.803-811, 2003. ,
DOI : 10.2337/diabetes.52.3.803
Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus ??? A pooled meta-analysis of randomized placebo-controlled clinical trials, International Journal of Cardiology, vol.141, issue.2, 2009. ,
DOI : 10.1016/j.ijcard.2008.11.211
Gemfibrozil in the Treatment of Dyslipidemia, Archives of Internal Medicine, vol.166, issue.7, pp.743-748, 2006. ,
DOI : 10.1001/archinte.166.7.743
Diabetes, Plasma Insulin, and Cardiovascular Disease, Archives of Internal Medicine, vol.162, issue.22, pp.2597-2604, 2002. ,
DOI : 10.1001/archinte.162.22.2597
Bezafibrate for the Secondary Prevention of Myocardial Infarction in Patients With Metabolic Syndrome, Archives of Internal Medicine, vol.165, issue.10, pp.1154-1160, 2005. ,
DOI : 10.1001/archinte.165.10.1154
Relation of clinical benefit of raising highdensity lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial ,
Atorvastatin and Micronized Fenofibrate Alone and in Combination in Type 2 Diabetes With Combined Hyperlipidemia, Diabetes Care, vol.25, issue.7, pp.1198-1202, 2002. ,
DOI : 10.2337/diacare.25.7.1198
Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome, The American Journal of Cardiology, vol.91, issue.8, pp.956-960, 2003. ,
DOI : 10.1016/S0002-9149(03)00111-5
Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial), The American Journal of Cardiology, vol.95, issue.4, pp.462-468, 2005. ,
DOI : 10.1016/j.amjcard.2004.10.012
Comparison of Effects of Simvastatin Alone Versus Fenofibrate Alone Versus Simvastatin Plus Fenofibrate on Lipoprotein Subparticle Profiles in Diabetic Patients With Mixed Dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen Study), The American Journal of Cardiology, vol.101, issue.4, pp.486-489, 2008. ,
DOI : 10.1016/j.amjcard.2007.09.095
Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: A phase 3, randomized, controlled study, American Heart Journal, vol.157, issue.1, pp.195-203, 2009. ,
DOI : 10.1016/j.ahj.2008.08.027
Efficacy and Safety of ABT-335 (Fenofibric Acid) in Combination With Atorvastatin in Patients With Mixed Dyslipidemia, The American Journal of Cardiology, vol.103, issue.4 ,
DOI : 10.1016/j.amjcard.2008.10.025
Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: A phase 3 study, Atherosclerosis, vol.204, issue.1, pp.208-215, 2009. ,
DOI : 10.1016/j.atherosclerosis.2008.09.027
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Design and Methods, The American Journal of Cardiology, vol.99, issue.12, pp.21-33, 2007. ,
DOI : 10.1016/j.amjcard.2007.03.003
ongoing for the lipid and blood pressure arms) documenting for the first time the benefits and risks of intensive glucose control, intensive blood pressure control, and the combination of fenofibrate and simvastatin in managing blood lipids in patients with T2DM ,
Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin, The American Journal of Cardiology, vol.95, issue.1, pp.120-122, 2005. ,
DOI : 10.1016/j.amjcard.2004.08.076
Effects of Fibrates on Metabolism of Statins in Human Hepatocytes, Drug Metabolism and Disposition, vol.30, issue.11, pp.1280-1287, 2002. ,
DOI : 10.1124/dmd.30.11.1280
ABT-335, the Choline Salt of Fenofibric Acid, Does Not Have a Clinically Significant Pharmacokinetic Interaction With Rosuvastatin in Humans, The Journal of Clinical Pharmacology, vol.54, issue.1, pp.63-71, 2009. ,
DOI : 10.1177/0091270008325671
Clinical Management of Metabolic Syndrome: Report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association Conference on Scientific Issues Related to Management, Circulation, vol.109, issue.4, pp.551-556, 2004. ,
DOI : 10.1161/01.CIR.0000112379.88385.67
Scandinavian Simvastatin Survival Study BIP : Bezafibrate Infarction Prevention PROVE-IT TIMI-22 : Pravastatin or Atorvastatin Evaluation and Infection Therapy- Thrombolysis in Myocardial Infarction 22 ,